MA27566A1 - Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4 - Google Patents

Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4

Info

Publication number
MA27566A1
MA27566A1 MA28338A MA28338A MA27566A1 MA 27566 A1 MA27566 A1 MA 27566A1 MA 28338 A MA28338 A MA 28338A MA 28338 A MA28338 A MA 28338A MA 27566 A1 MA27566 A1 MA 27566A1
Authority
MA
Morocco
Prior art keywords
inhibitors
naphthyridine
dihydro
oxo
phenyl substituted
Prior art date
Application number
MA28338A
Other languages
English (en)
Inventor
Daniel Dube
Michel Gallant
Patrick Lacombe
Renee Aspiotis
Laurence Dube
Yves Girard
Dwight Macdonald
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of MA27566A1 publication Critical patent/MA27566A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés représentés par la formule (I), y compris leurs sels pharmaceutiquement acceptables, qui sont des inhibiteurs de phosphodiestérase-4 utiles dans le traitement de l'asthme et de l'inflammation et utiles comme améliorants cognitifs
MA28338A 2002-11-22 2005-06-16 Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4 MA27566A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42861102P 2002-11-22 2002-11-22

Publications (1)

Publication Number Publication Date
MA27566A1 true MA27566A1 (fr) 2005-10-03

Family

ID=32393431

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28338A MA27566A1 (fr) 2002-11-22 2005-06-16 Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4

Country Status (23)

Country Link
US (2) US7342024B2 (fr)
EP (1) EP1565464B1 (fr)
JP (1) JP4499571B2 (fr)
KR (1) KR20050085112A (fr)
CN (1) CN100475813C (fr)
AT (1) ATE402175T1 (fr)
AU (1) AU2003283167B2 (fr)
BR (1) BR0316458A (fr)
CA (1) CA2506648C (fr)
CL (1) CL2004001050A1 (fr)
DE (1) DE60322417D1 (fr)
EC (1) ECSP055809A (fr)
HR (1) HRP20050451A2 (fr)
IS (1) IS7839A (fr)
MA (1) MA27566A1 (fr)
MX (1) MXPA05005413A (fr)
NO (1) NO20053046L (fr)
NZ (1) NZ539812A (fr)
PL (1) PL377237A1 (fr)
RU (1) RU2312865C2 (fr)
UA (1) UA82208C2 (fr)
WO (1) WO2004048374A1 (fr)
ZA (1) ZA200503586B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
EP1981885A2 (fr) * 2005-10-27 2008-10-22 Merck & Co., Inc. Procede de preparation d'inhibiteur de 4-oxo-1-(3-phenyle substitue)-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4
AR057555A1 (es) * 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
RS53461B (en) 2006-07-05 2014-12-31 Takeda Gmbh COMBINATION OF HMG-COA REDUCTASE INHIBITOR OR SIMVASTATIN WITH PHOSPHODIESTERASE 4 INHIBITOR AS A ROFLUMILAST FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
PT2074123E (pt) * 2006-10-16 2013-01-22 Bionomics Ltd Novos compostos ansiolíticos
NZ579645A (en) * 2007-03-14 2012-01-12 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
TW200951139A (en) 2008-05-27 2009-12-16 Astrazeneca Ab Chemical compounds 293
MX2012003693A (es) * 2009-10-01 2012-04-19 Alcon Res Ltd Composiciones de olopatadine y usos de las mismas.
US9376424B2 (en) * 2010-07-01 2016-06-28 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
JP2014510065A (ja) 2011-03-02 2014-04-24 バイオノミックス リミテッド 治療薬としての新規な小分子
JP6055817B2 (ja) 2011-05-12 2016-12-27 バイオノミックス リミテッド ナフチリジンの調製方法
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2861571B1 (fr) * 2012-06-15 2017-05-03 Bio-Pharm Solutions Co., Ltd. Composé de sulfamate de phénylalkyle et composition myorelaxante le contenant
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN106316824B (zh) * 2016-08-18 2018-10-19 广州康瑞泰药业有限公司 一种合成2-氟环丙烷甲酸的新方法
WO2018108167A1 (fr) * 2016-12-16 2018-06-21 基石药业 Inhibiteur de cdk4/6
CN113423435A (zh) 2018-12-28 2021-09-21 雷杰纳荣制药公司 使用花生四烯酸15-脂氧合酶(alox15)抑制剂治疗呼吸系统病症

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808070A1 (de) * 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US5328908A (en) * 1988-10-24 1994-07-12 Procter & Gamble Pharmaceuticals, Inc. Antimicrobial quinolone thioureas
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
CN1043993C (zh) * 1994-08-29 1999-07-07 山之内制药株式会社 萘啶衍生物及其医药组合物
ATE258437T1 (de) * 1995-08-02 2004-02-15 Darwin Discovery Ltd Chinolone und deren therapeutische verwendung
JPH11106385A (ja) * 1997-08-06 1999-04-20 Suntory Ltd Ｉｖ型ホスホジエステラーゼ阻害作用を有する１−アリール−１，８−ナフチリジン−４−オン誘導体
HUP0001054A3 (en) * 1997-08-06 2001-01-29 Daiichi Asubio Pharma Co Ltd 1-aryl-1,8-naphthyridin-4-one derivative as type iv phosphodiesterase inhibitor
ES2195571T3 (es) * 1998-05-05 2003-12-01 Altana Pharma Ag Nuevos benzonaftiridin-n-oxidos.
US6794447B1 (en) * 2000-07-28 2004-09-21 Taylor Made Golf Co., Inc. Golf balls incorporating nanocomposite materials
AU2002257459B2 (en) * 2001-05-24 2006-12-14 Merck Frosst Canada Ltd 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
KR100824233B1 (ko) * 2001-10-10 2008-04-24 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난3,4-디하이드로-1ｈ-나프탈렌 유도체
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar

Also Published As

Publication number Publication date
US20050107402A1 (en) 2005-05-19
PL377237A1 (pl) 2006-01-23
WO2004048374A1 (fr) 2004-06-10
ATE402175T1 (de) 2008-08-15
JP2006508989A (ja) 2006-03-16
ZA200503586B (en) 2006-07-26
EP1565464B1 (fr) 2008-07-23
NO20053046D0 (no) 2005-06-21
CN1738819A (zh) 2006-02-22
BR0316458A (pt) 2005-10-11
RU2005119644A (ru) 2006-01-20
CN100475813C (zh) 2009-04-08
HRP20050451A2 (en) 2006-02-28
US7342024B2 (en) 2008-03-11
CA2506648A1 (fr) 2004-06-10
NZ539812A (en) 2007-12-21
ECSP055809A (es) 2005-08-11
AU2003283167A1 (en) 2004-06-18
IS7839A (is) 2004-05-23
CL2004001050A1 (es) 2005-03-28
AU2003283167B2 (en) 2009-01-08
UA82208C2 (en) 2008-03-25
JP4499571B2 (ja) 2010-07-07
CA2506648C (fr) 2011-01-25
NO20053046L (no) 2005-07-27
EP1565464A1 (fr) 2005-08-24
RU2312865C2 (ru) 2007-12-20
KR20050085112A (ko) 2005-08-29
DE60322417D1 (en) 2008-09-04
MXPA05005413A (es) 2005-08-03
US7238706B2 (en) 2007-07-03
US20060058316A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
MA27566A1 (fr) Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
TW200519111A (en) N3-substituted imidazopyridine C-KIT inhibitors
SE9903760D0 (sv) New compounds
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
AU2002246728A1 (en) Carboline derivatives
TW200801006A (en) Fused bicyclic mTOR inhibitors
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
NO20052182L (no) Nye forbindelser
ECSP055844A (es) Nuevos compuestos triciclicos
AU2002249890A1 (en) Carboline derivatives
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
CA2474510A1 (fr) Heterocycles tricycliques fusionnes utilises dans le traitement de troubles hyperproliferatifs
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
AU2002213419A1 (en) Condensed pyridoindole derivatives
SE0302756D0 (sv) Novel Compounds
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU2003258630A1 (en) Pyrimidine derivatives as selective cox-2 inhibitors
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
AU2001261707A1 (en) Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives
GB0319037D0 (en) 7-Azaindole Derivatives
AU2003297363A1 (en) Use of cathepsin k inhibitors for the treatment of glaucoma
IS8034A (is) Imídasó[4,5-B]kínólínafleiður og notkun þeirra sem NO-myndunarhemla